ETrade Capital Management’s Pacira BioSciences PCRX Stock Holding History

ETrade Capital Management’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	$768K	Sell	12,772 -599	-4%	-$34.8K	0.01%	452
2020 Q2	$702K	Sell	13,371 -384	-3%	-$16K	0.01%	464
2020 Q1	$461K	Sell	13,755 -766	-5%	-$31.8K	0.01%	490
2019 Q4	$658K	Buy	14,521 +7,291	+101%	+$310K	0.01%	481
2019 Q3	$275K	Buy	7,230 +155	+2%	+$6.19K	0.01%	698
2019 Q2	$308K	Sell	7,075 -572	-7%	-$24.3K	0.01%	679
2019 Q1	$291K	Buy	+7,647	New	+$298K	0.01%	685
2017 Q4	–	Sell	-10,664	Closed	-$400K	–	759
2017 Q3	$400K	Buy	10,664 +846	+9%	+$34K	0.01%	525
2017 Q2	$468K	Sell	9,818 -2,802	-22%	-$130K	0.02%	471
2017 Q1	$575K	Buy	+12,620	New	+$545K	0.02%	406

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

SCM

Spyglass Capital Management San Francisco, California $1.41B AUM 7.96% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

ETrade Capital Management's PCRX Position: Q3 2020 in Review

ETrade Capital Management reduced its Pacira BioSciences (PCRX) stake by 4.5% in Q3 2020, selling an estimated $34.8K and leaving 12,772 shares worth $768K. The position accounts for 0.01% of the portfolio, ranked #452.

ETrade Capital Management first reported a position in PCRX in Q1 2017 and has held it in 10 quarters since. 257 funds tracked by Wall St. Rank hold PCRX as of Q3 2020.

ETrade Capital Management held 12,772 shares of Pacira BioSciences worth $768K as of Q3 2020.
ETrade Capital Management sold 599 Pacira BioSciences shares in Q3 2020, an estimated $34.8K.
Pacira BioSciences made up 0.01% of ETrade Capital Management's portfolio in Q3 2020, its #452 holding.
ETrade Capital Management first reported a position in Pacira BioSciences in Q1 2017 and has held it in 10 quarters since.
257 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2020.

Based on ETrade Capital Management's 13F filing for Q3 2020, filed 13 Nov 2020.